Literature DB >> 24747372

Assessing functional performance in the mdx mouse model.

Annemieke Aartsma-Rus1, Maaike van Putten2.   

Abstract

Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder for which no cure is available. Nevertheless, several potential pharmaceutical compounds and gene therapy approaches have progressed into clinical trials. With improvement in muscle function being the most important end point in these trials, a lot of emphasis has been placed on setting up reliable, reproducible, and easy to perform functional tests to pre clinically assess muscle function, strength, condition, and coordination in the mdx mouse model for DMD. Both invasive and noninvasive tests are available. Tests that do not exacerbate the disease can be used to determine the natural history of the disease and the effects of therapeutic interventions (e.g. forelimb grip strength test, two different hanging tests using either a wire or a grid and rotarod running). Alternatively, forced treadmill running can be used to enhance disease progression and/or assess protective effects of therapeutic interventions on disease pathology. We here describe how to perform these most commonly used functional tests in a reliable and reproducible manner. Using these protocols based on standard operating procedures enables comparison of data between different laboratories.

Entities:  

Mesh:

Year:  2014        PMID: 24747372      PMCID: PMC4158772          DOI: 10.3791/51303

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  21 in total

1.  Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.

Authors:  Paul S Sharp; Hema Bye-a-Jee; Dominic J Wells
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Strain-dependent differences in responses to exercise training in inbred and hybrid mice.

Authors:  Michael P Massett; Bradford C Berk
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-12-23       Impact factor: 3.619

3.  Noninvasive in vivo assessment of muscle impairment in the mdx mouse model--a comparison of two common wire hanging methods with two different results.

Authors:  Silvan M Klein; Jody Vykoukal; Philipp Lechler; Katharina Zeitler; Sebastian Gehmert; Stephan Schreml; Eckhard Alt; Ulrich Bogdahn; Lukas Prantl
Journal:  J Neurosci Methods       Date:  2011-10-12       Impact factor: 2.390

4.  Early development of synchronized walking on the rotorod in rats. Effects of training and handling.

Authors:  P Chapillon; R Lalonde; N Jones; J Caston
Journal:  Behav Brain Res       Date:  1998-06       Impact factor: 3.332

5.  Systemic administration of PRO051 in Duchenne's muscular dystrophy.

Authors:  Nathalie M Goemans; Mar Tulinius; Johanna T van den Akker; Brigitte E Burm; Peter F Ekhart; Niki Heuvelmans; Tjadine Holling; Anneke A Janson; Gerard J Platenburg; Jessica A Sipkens; J M Ad Sitsen; Annemieke Aartsma-Rus; Gert-Jan B van Ommen; Gunnar Buyse; Niklas Darin; Jan J Verschuuren; Giles V Campion; Sjef J de Kimpe; Judith C van Deutekom
Journal:  N Engl J Med       Date:  2011-03-23       Impact factor: 91.245

6.  A single 30 min treadmill exercise session is suitable for 'proof-of concept studies' in adult mdx mice: a comparison of the early consequences of two different treadmill protocols.

Authors:  Hannah Radley-Crabb; Jessica Terrill; Thea Shavlakadze; Joanne Tonkin; Peter Arthur; Miranda Grounds
Journal:  Neuromuscul Disord       Date:  2011-08-10       Impact factor: 4.296

7.  Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice.

Authors:  Raffaella Willmann; Annamaria De Luca; Michael Benatar; Miranda Grounds; Judith Dubach; Jean-Marc Raymackers; Kanneboyina Nagaraju
Journal:  Neuromuscul Disord       Date:  2011-07-06       Impact factor: 4.296

8.  First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up.

Authors:  Daniel Skuk; Marlyne Goulet; Brigitte Roy; Vincent Piette; Claude H Côté; Pierre Chapdelaine; Jean-Yves Hogrel; Martin Paradis; Jean-Pierre Bouchard; Michel Sylvain; Jean-Guy Lachance; Jacques P Tremblay
Journal:  Neuromuscul Disord       Date:  2006-12-04       Impact factor: 4.296

9.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Authors:  Sebahattin Cirak; Virginia Arechavala-Gomeza; Michela Guglieri; Lucy Feng; Silvia Torelli; Karen Anthony; Stephen Abbs; Maria Elena Garralda; John Bourke; Dominic J Wells; George Dickson; Matthew J A Wood; Steve D Wilton; Volker Straub; Ryszard Kole; Stephen B Shrewsbury; Caroline Sewry; Jennifer E Morgan; Kate Bushby; Francesco Muntoni
Journal:  Lancet       Date:  2011-07-23       Impact factor: 79.321

10.  The effects of low levels of dystrophin on mouse muscle function and pathology.

Authors:  Maaike van Putten; Margriet Hulsker; Vishna Devi Nadarajah; Sandra H van Heiningen; Ella van Huizen; Maarten van Iterson; Peter Admiraal; Tobias Messemaker; Johan T den Dunnen; Peter A C 't Hoen; Annemieke Aartsma-Rus
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more
  66 in total

1.  Myelinating Glia-Specific Deletion of Fbxo7 in Mice Triggers Axonal Degeneration in the Central Nervous System Together with Peripheral Neuropathy.

Authors:  Sabitha Joseph; Siv Vingill; Olaf Jahn; Robert Fledrich; Hauke B Werner; Istvan Katona; Wiebke Möbius; Mišo Mitkovski; Yuhao Huang; Joachim Weis; Michael W Sereda; Jörg B Schulz; Klaus-Armin Nave; Judith Stegmüller
Journal:  J Neurosci       Date:  2019-05-13       Impact factor: 6.167

2.  Suite of clinically relevant functional assays to address therapeutic efficacy and disease mechanism in the dystrophic mdx mouse.

Authors:  Yafeng Song; Shira T Rosenblum; Leon Morales; Mihail Petrov; Christopher Greer; Samantha Globerman; Hansell H Stedman
Journal:  J Appl Physiol (1985)       Date:  2016-12-08

3.  Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA.

Authors:  Heng Li; Hironori Okada; Sadafumi Suzuki; Kazuhisa Sakai; Hitomi Izumi; Yukiko Matsushima; Noritaka Ichinohe; Yu-Ichi Goto; Takashi Okada; Ken Inoue
Journal:  JCI Insight       Date:  2019-05-16

4.  Mitochondrial FAD shortage in SLC25A32 deficiency affects folate-mediated one-carbon metabolism.

Authors:  Min-Zhi Peng; Yong-Xian Shao; Xiu-Zhen Li; Kang-Di Zhang; Yan-Na Cai; Yun-Ting Lin; Min-Yan Jiang; Zong-Cai Liu; Xue-Ying Su; Wen Zhang; Xiao-Ling Jiang; Li Liu
Journal:  Cell Mol Life Sci       Date:  2022-06-21       Impact factor: 9.261

5.  KLF15 overexpression in myocytes fails to ameliorate ALS-related pathology or extend the lifespan of SOD1G93A mice.

Authors:  Ryan Massopust; Devin Juros; Dillon Shapiro; Mikayla Lopes; Saptarsi M Haldar; Thomas Taetzsch; Gregorio Valdez
Journal:  Neurobiol Dis       Date:  2021-12-11       Impact factor: 5.996

6.  Lysosomal K+ channel TMEM175 promotes apoptosis and aggravates symptoms of Parkinson's disease.

Authors:  Lili Qu; Bingqian Lin; Wenping Zeng; Chunhong Fan; Haotian Wu; Yushu Ge; Qianqian Li; Canjun Li; Yanan Wei; Jing Xin; Xingbing Wang; Dan Liu; Chunlei Cang
Journal:  EMBO Rep       Date:  2022-08-01       Impact factor: 9.071

7.  Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.

Authors:  Fabio Arturo Iannotti; Ester Pagano; Aniello Schiano Moriello; Filomena Grazia Alvino; Nicolina Cristina Sorrentino; Luca D'Orsi; Elisabetta Gazzerro; Raffaele Capasso; Elvira De Leonibus; Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

8.  Inhibition of microRNA-92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy-related phenotype in mdx mice.

Authors:  Mayank Verma; Yoko Asakura; Atsushi Asakura
Journal:  Muscle Nerve       Date:  2019-02-23       Impact factor: 3.217

9.  pH-Responsive Polymer Nanoparticles for Efficient Delivery of Cas9 Ribonucleoprotein With or Without Donor DNA.

Authors:  Ruosen Xie; Xiuxiu Wang; Yuyuan Wang; Mingzhou Ye; Yi Zhao; Brian S Yandell; Shaoqin Gong
Journal:  Adv Mater       Date:  2022-04-28       Impact factor: 32.086

10.  Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis.

Authors:  Zheng Yu; Meiying Zhang; Hongyang Jing; Peng Chen; Rangjuan Cao; Jinxiu Pan; Bin Luo; Yue Yu; Brandy M Quarles; Wencheng Xiong; Michael H Rivner; Lin Mei
Journal:  Neurology       Date:  2021-07-07       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.